Arabic Arabic English English French French German German
dark

FDA Accepts GMP Plasmid DMF and Capacity Expansion Enabling Andelyn Biosciences to Offer Faster Gene Therapy Development

Andelyn Biosciences, a pioneering cell and gene therapy CDMO born out of Nationwide Children’s Hospital, announced the U.S. FDA’s acceptance of its GMP plasmid DNA drug master file, which enables the organization to vertically integrate its clients’ manufacturing process, condensing timelines for developers to begin manufacturing to just three months. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

BridgeBio and Amgen Unite on Combination Therapy for Advanced Solid Tumors

Next Post

FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

Related Posts
Total
0
Share